Mark P. Backer
Director/Board Member at Molecular Medicine BioServices, Inc.
Profile
Mark P.
Backer is currently the Director at Molecular Medicine BioServices, Inc., a Member at American Institute of Chemical Engineers, and a Member at Parenteral Drug Association.
He previously worked as the Chairman at Genentech, Inc., Development Director at Systemix, Inc. and Coulter Pharmaceuticals, Inc., Principal at Eli Lilly & Co., MedImmune Vaccines, Inc., and IDEC Pharmaceuticals Corp., Chief Operating Officer at Vaxart, Inc., and Senior Vice President-Technical Operations at SillaJen Biotherapeutics, Inc. He also served as the Vice President-Technical Development at PDL BioPharma, Inc. from 2001 to 2005.
Dr. Backer received his undergraduate degree from Stanford University and his doctorate from the University of Washington.
Mark P. Backer active positions
| Companies | Position | Start |
|---|---|---|
Molecular Medicine BioServices, Inc.
 Molecular Medicine BioServices, Inc. Pharmaceuticals: MajorHealth Technology Molecular Medicine BioServices, Inc. is a company that provides services in the pharmaceutical industry. The company is based in Carlsbad, CA. The company has signed a manufacturing agreement with Cardium Therapeutics for the production of Generx and have expanded their services to better serve client vaccine development and testing needs. The company was acquired by Sigma-Aldrich Corp., part of Merck KGaA on November 19, 2015. | Director/Board Member | - |
| Parenteral Drug Association | Corporate Officer/Principal | - |
American Institute of Chemical Engineers
 American Institute of Chemical Engineers Miscellaneous Commercial ServicesCommercial Services The American Institute of Chemical Engineers (AIChE) is a professional society with over 60,000 members in more than 110 countries. The private company is based in New York, NY, and has subsidiaries in the United States. AIChE offers various programs, including e-learning, webinars, and career advancement, to help chemical engineers at every career juncture bridge the skills gap created by the rush of technology, changing work styles, and unprecedented societal needs. Founded in 1908, AIChE is a focal point for information exchange on the frontiers of chemical engineering research in areas such as energy, sustainability, biological and environmental engineering, nanotechnology, and chemical plant safety and security. | Corporate Officer/Principal | - |
Former positions of Mark P. Backer
| Companies | Position | End |
|---|---|---|
| PDL BIOPHARMA, INC. | Corporate Officer/Principal | 2005-12-29 |
MedImmune Vaccines, Inc.
 MedImmune Vaccines, Inc. BiotechnologyHealth Technology MedImmune Vaccines, Inc. develops, manufactures and markets live vaccines. Its developed vaccine is inhaled FluMist. The company is located in Mountain View, CA | Corporate Officer/Principal | - |
Coulter Pharmaceuticals, Inc.
 Coulter Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 1995, Coulter Pharmaceutical is engaged in the development of novel drugs and therapies for the treatment of people with cancer and autoimmune diseases. Currently under development is a family of therapeutics based upon two drug discovery platforms: therapeutic antibodies and targeted oncologics. | Corporate Officer/Principal | - |
Systemix, Inc.
 Systemix, Inc. Medical/Nursing ServicesHealth Services Systemix, Inc. develops cell-based gene therapies for diseases. The company is based in Palo Alto, CA. The company was founded by Irving L. Weissman, Leroy E. Hood. Systemix was acquired by Novartis AG on February 14, 1997 for $75.90 million. | Corporate Officer/Principal | - |
IDEC Pharmaceuticals Corp.
 IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | Corporate Officer/Principal | - |
Training of Mark P. Backer
| Stanford University | Undergraduate Degree |
| University of Washington | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| Private companies | 11 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Systemix, Inc.
Systemix, Inc. Medical/Nursing ServicesHealth Services Systemix, Inc. develops cell-based gene therapies for diseases. The company is based in Palo Alto, CA. The company was founded by Irving L. Weissman, Leroy E. Hood. Systemix was acquired by Novartis AG on February 14, 1997 for $75.90 million. | Health Services |
MedImmune Vaccines, Inc.
MedImmune Vaccines, Inc. BiotechnologyHealth Technology MedImmune Vaccines, Inc. develops, manufactures and markets live vaccines. Its developed vaccine is inhaled FluMist. The company is located in Mountain View, CA | Health Technology |
Coulter Pharmaceuticals, Inc.
Coulter Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 1995, Coulter Pharmaceutical is engaged in the development of novel drugs and therapies for the treatment of people with cancer and autoimmune diseases. Currently under development is a family of therapeutics based upon two drug discovery platforms: therapeutic antibodies and targeted oncologics. | Health Technology |
Molecular Medicine BioServices, Inc.
Molecular Medicine BioServices, Inc. Pharmaceuticals: MajorHealth Technology Molecular Medicine BioServices, Inc. is a company that provides services in the pharmaceutical industry. The company is based in Carlsbad, CA. The company has signed a manufacturing agreement with Cardium Therapeutics for the production of Generx and have expanded their services to better serve client vaccine development and testing needs. The company was acquired by Sigma-Aldrich Corp., part of Merck KGaA on November 19, 2015. | Health Technology |
Vaxart, Inc. /Old/
 Vaxart, Inc. /Old/ BiotechnologyHealth Technology Vaxart, Inc. develops technology for oral vaccination against infectious agents. Its products in pipeline include H1N1 seasonal influenza vaccine and oral H5N1 avian influenza vaccine. The firm develops oral recombinant vaccines based on its proprietary oral vaccine delivery platform. The company was founded by Sean N. Tucker in 2004 and is headquartered in San Francisco, CA. | Health Technology |
SillaJen Biotherapeutics, Inc.
 SillaJen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA. | Commercial Services |
IDEC Pharmaceuticals Corp.
IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | Health Technology |
PDL BioPharma, Inc.
 PDL BioPharma, Inc. BiotechnologyHealth Technology PDL BioPharma, Inc. engages in the business of developing innovative therapeutics and healthcare technologies. It operates under the Medical Devices and Income Generating Assets segments. The Medical Devices segment focuses on the sale and lease of the LENSAR laser system which includes equipment, patient interface devices, procedure licenses, training, installation, warranty, and maintenance agreements. The Income Generating Assets segment offers notes and other long-term receivables; royalty rights, hybrid notes, and royalty receivables; equity investments; and royalties from issued patents covering the humanization of antibodies. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Reno, NV. | Health Technology |
American Institute of Chemical Engineers
American Institute of Chemical Engineers Miscellaneous Commercial ServicesCommercial Services The American Institute of Chemical Engineers (AIChE) is a professional society with over 60,000 members in more than 110 countries. The private company is based in New York, NY, and has subsidiaries in the United States. AIChE offers various programs, including e-learning, webinars, and career advancement, to help chemical engineers at every career juncture bridge the skills gap created by the rush of technology, changing work styles, and unprecedented societal needs. Founded in 1908, AIChE is a focal point for information exchange on the frontiers of chemical engineering research in areas such as energy, sustainability, biological and environmental engineering, nanotechnology, and chemical plant safety and security. | Commercial Services |
| Parenteral Drug Association |
- Stock Market
- Insiders
- Mark P. Backer